Sector News

Will flush-with-cash Big Pharma beat Takeda to a Shire deal?

April 3, 2018
Life sciences

Takeda hasn’t even approached Shire with a buyout offer yet, but its mere plans to submit one could spark competing bids. And the competition could happen quickly, thanks to U.K. takeover rules. “If there are other bidders, they would arguably need to mobilize in the near term,” Jefferies analyst David Steinberg explained.

The Japanese drugmaker’s Wednesday interest announcement started a ticking clock. Under those rules, Takeda must stipulate submit a bid by April 25 or walk away.

The way Steinberg sees it, because of Shire’s near-term “challenges in the hemophilia market”—think new competition from Roche’s Hemlibra—investors “could perhaps be amenable to another $50 billion-plus bid from interested parties.”

Those parties would likely include Big Pharmas, many of which boast increased dealmaking bandwidth with U.S. tax reform. In December, The Telegraph reported that several large drugmakers from both sides of the pond were rumored to be circling the hard-hit biotech.

“We expect most large cap pharma companies have a takeout model of Shire,” Bernstein analyst Ronny Gal wrote in his own note to clients, adding that, “Takeda’s announcement will force them to make a decision” about “whether they want to step up.”

Ever-deal-ready Pfizer and AbbVie—which has already agreed once to buy Shire, only to see its efforts scuttled by U.S. Treasury laws—are “the names referenced most often,” Gal noted, and they’re also two of the biggest beneficiaries of the tax changes.

Neither, though, is a “perfect suitor,” he wrote, and they’ve also both “been discussed as having preference elsewhere.” Pfizer, in particular, has long been rumored to be eying Bristol-Myers Squibb and/or AstraZeneca, both key immuno-oncology players that could vault Pfizer’s position in the lucrative field.

Meanwhile, it’s unclear how Takeda—whose valuation sits below Shire’s—would fund a transaction, especially considering that both are shouldering a “fair amount of debt,” Steinberg pointed out. Takeda’s sitting with $11 billion, while Shire’s racked up $19 billion.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

January 23, 2022

UCB to acquire Zogenix

Life sciences

UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.

January 23, 2022

argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis

Life sciences

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).

January 23, 2022

GlaxoSmithKline rejects Unilever’s $68B consumer health buyout offer, but a bigger bid is brewing

Life sciences

GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.

Send this to a friend